Potential Role of Nanostructured Lipid Carrier as Cutting-Edge Approach for Drug Delivery of Nonsteroidal Anti-Inflammatory Drugs
Abstract
The majority of nonsteroidal anti-inflammatory drugs (NSAIDs) are categorised as Biopharmaceutics Classification System (BCS) class II or IV drugs, indicate their limited solubility and permeability. The nanostructured lipid carriers (NLCs) can be utilised in drug delivery of NSAIDs to decrease adverse effects and create controlled-release oral formulations. The utilisation of NLCs in transdermal and topical formulations of NSAIDs has demonstrated better efficacy in alleviating inflammation and pain, both at the site of application and throughout the body. This review offers concise insights into the characteristics and mode of action of NSAIDs in the inflammatory cascade. The current review provides a complete overview of the advanced functions of NLCs in delivering NSAIDs through various routes of administrations, including buccal, cutaneous, transdermal, ocular, oral controlled, parenteral and pulmonary routes. To accomplish this objective, an extensive literature search was conducted utilising the ScienceDirect, PubMed and Google Scholar databases. A systematic review was undertaken using scholarly publications published in peer-reviewed journals from 2000 to 2024. Research has established that NLCs possess considerable potential in offering diverse benefits in the delivery of NSAIDs. These benefits include improved skin penetration and precise targeting when applied topically, enhanced drug retention on the corneal surface and effective transport across ocular barriers when administered to the eyes, extended drug residence period in the lungs and increased diffusion mobility when administered through the pulmonary route, as well as prolonged and sustained duration of action when administered buccally, parenterally, or orally. This analysis emphasises the considerable capacity of NLCs to efficiently transport NSAIDs while reducing their negative impacts in the management of inflammatory diseases.
References
Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020;180:114147. doi: 10.1016/j.bcp.2020.114147.
Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother 2018;103:598-613. doi: 10.1016/j.biopha.2018.04.055.
Elmowafy M, Al-Sanea MM. Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies. Saudi Pharm J. 2021;29(9):999-1012. doi: 10.1016/j.jsps.2021.07.015.
Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-24. doi: 10.1038/s41573-020-0090-8.
Syed Azhar SN, Ashari SE, Zainuddin N, Hassan M. Nanostructured lipid carriers-hydrogels system for drug delivery: Nanohybrid technology perspective. Molecules. 2022;27(1):289. doi: 10.3390/molecules27010289.
Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: A novel drug targeting carrier. J Drug Deliv Sci Technol. 2019;51:255-67. doi: 10.1016/j.jddst.2019.02.017.
Khan S, Baboota S, Ali J, Khan S, Narang RS, Narang JK. Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugs. Int J Pharm Investig. 2015;5(4):182. doi: 10.4103/2230-973X.167661.
Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol. 2016;44(1):27-40. doi: 10.3109/21691401.2014.909822.
Beloqui A, del Pozo-Rodríguez A, Isla A, Rodríguez-Gascón A, Solinís MÁ. Nanostructured lipid carriers as oral delivery systems for poorly soluble drugs. J Drug Deliv Sci Technol. 2017;42:144-54. doi: 10.1016/j.jddst.2017.06.013.
Shidhaye SS, Vaidya R, Sutar S, Patwardhan A, Kadam VJ. Solid lipid nanoparticles and nanostructured lipid carriers-innovative generations of solid lipid carriers. Curr Drug Deliv. 2008;5(4):324-31. doi: 10.2174/156720108785915087.
Li Q, Cai T, Huang Y, Xia X, Cole SP, Cai Y. A review of the structure, preparation, and application of NLCs, PNPs and PLNs. Nanomaterials. 2017;7(6):122. doi: 10.3390/nano7060122.
Haider M, Abdin SM, Kamal L, Orive G. Nanostructured lipid carriers for delivery of chemotherapeutics: A review. Pharmaceutics. 2020;12(3):288. doi: 10.3390/pharmaceutics12030288.
Jafari S, Bakhshaei A, Eskandani M, Molavi O. Silibinin-loaded nanostructured lipid carriers for growth inhibition of cisplatin-resistant ovarian cancer cells. Assay Drug Dev Technol. 2022;20(8):339-48. doi: 10.1089/adt.2022.060.
Alhalmi A, Amin S, Khan Z, Beg S, Al Kamaly O, Saleh A, Kohli K. Nanostructured lipid carrier-based codelivery of raloxifene and naringin: formulation, optimization, in-vitro, ex-vivo, in vivo assessment, and acute toxicity studies. Pharmaceutics. 2022;14(9):1771. doi: 10.3390/pharmaceutics14091771.
Khan S, Sharma A, Jain V. An overview of nanostructured lipid carriers and its application in drug delivery through different routes. Adv Pharm Bull. 2023;13(3):446-60. doi: 10.34172/apb.2023.056.
Khang VC, Nhan NP, Cang MH. Fabrication of nanostructured lipid carriers (NLC) for encapsulation of gac (Momordica cochinchinensis) oil by using homogenization method. AIP Conf Proc. 2022;2610(1):060017. doi: 10.1063/5.0101285.
Lade S, Shah N, Burle S. Nanostructured Lipid Carriers: A vital drug carrier for migraine treatment. Res J Pharm Technol. 2022;15(7):3309-16. doi: 10.52711/0974-360X.2022.00554.
Hassan Dh, Shohdy Jn, El-Nabarawi Ma, El-Setouhy Da, Abdellatif Mm. Nanostructured lipid carriers for transdermal drug delivery. Int J App Pharm. 2022;14(4):88-93. doi: 10.22159/ijap.2022v14i4.44564.
Van NH, Vy NT, Van Toi V, Dao AH, Lee BJ. Nanostructured lipid carriers and their potential applications for versatile drug delivery via oral administration. OpenNano. 2022;8:100064. doi: 10.1016/j.onano.2022.100064.
Gomaa E, Fathi HA, Eissa NG, Elsabahy M. Methods for preparation of nanostructured lipid carriers. Methods. 2022;199:3-8. doi: 10.1016/j.ymeth.2021.05.003.
Faiz S, Arshad S, Kamal Y, Imran S, Asim MH, Mahmood A, et al. Pioglitazone-loaded nanostructured lipid carriers: In-vitro and in-vivo evaluation for improved bioavailability. J Drug Deliv Sci Technol. 2022;79:104041. doi: 10.1016/j.jddst.2022.104041.
Chutoprapat R, Kopongpanich P, Chan LW. A mini-review on solid lipid nanoparticles and nanostructured lipid carriers: topical delivery of phytochemicals for the treatment of acne vulgaris. Molecules. 2022;27(11):3460. doi: 10.3390/molecules27113460.
Javed S, Mangla B, Almoshari Y, Sultan MH, Ahsan W. Nanostructured lipid carrier system: A compendium of their formulation development approaches, optimization strategies by quality by design, and recent applications in drug delivery. Nanotechnol Rev. 2022;11(1):1744-77. doi: 10.1515/ntrev-2022-0109.
Emami J, Rezazadeh M, Varshosaz J, Tabbakhian M, Aslani A. Formulation of LDL targeted nanostructured lipid carriers loaded with paclitaxel: a detailed study of preparation, freeze drying condition, and in-vitro cytotoxicity. J Nanomater. 2012;2012(1):358782. doi: 10.5402/2012/209573.
Sathish T, Giri J, Rathinasamy S, Kanan M. Optimization of docetaxel-loaded cholesterol nanostructured lipid carriers for improving cancer treatment using taguchi experimental design. Results Eng. 2024;103263. doi: 10.1016/j.rineng.2024.103263.
Alatawi HM, Alhwiti SS, Alsharif KA, Albalawi SS, Abusaleh SM, Sror GK, et al. Nanostructured lipid carriers (NLCs) as effective drug delivery systems: methods of preparation and their therapeutic applications. Recent Pat Nanotechnol 2024;18(2):179-89. doi: 10.2174/1872210517666230120142439.
Godase SS, Kulkarni NS, Dhole SN. A Comprehensive review on novel lipid-based nano drug delivery. Adv Pharm Bull 2024;14(1):34. doi: 10.34172/apb.2024.012.
Soni S, Maheshwari RK, Sah AK. nanostructured lipid carrier: beneficial role in oral drug delivery system. BioNanoSci. 2024; 3988–4005. doi: 10.1007/s12668-024-01416-x.
Liu K, Sun J, Wang Y, He Y, Gao K, He Z. Preparation and characterization of 10-hydroxycamptothecin loaded nanostructured lipid carriers. Drug Dev Ind Pharm. 2008;34(5):465-71. doi: 10.1080/03639040701662230.
Fang G, Tang B, Chao Y, Zhang Y, Xu H, Tang X. Improved oral bioavailability of docetaxel by nanostructured lipid carriers: in-vitro characteristics, in vivo evaluation and intestinal transport studies. RSC Adv 2015;5(117):96437-47. doi: 10.1039/C5RA14588K.
Qidwai A, Khan S, Md S, Fazil M, Baboota S, Narang JK, Ali J. Nanostructured lipid carrier in photodynamic therapy for the treatment of basal-cell carcinoma. Drug Deliv. 2016;23(4):1476-85. doi: 10.3109/10717544.2016.1165310.
Jain K, Sood S, Gowthamarajan K. Optimization of artemether-loaded NLC for intranasal delivery using central composite design. Drug Deliv. 2015;22(7):940-54. doi: 10.3109/10717544.2014.885999.
Shi L, Li Z, Yu L, Jia H, Zheng L. Effects of surfactants and lipids on the preparation of solid lipid nanoparticles using double emulsion method. J Dispers Sci Technol. 2011;32(2):254-9. doi: 10.1080/01932691003659130.
Üner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie. 2006;61(5):375-86. PMID: 16724531.
Ganesan P, Narayanasamy D. Lipid nanoparticles: Different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustain Chem Pharm. 2017;6:37-56. doi: 10.1016/j.scp.2017.07.002.
Nsairat H, Khater D, Odeh F, Al-Adaileh F, Al-Taher S, Jaber AM, et al. Lipid nanostructures for targeting brain cancer. Heliyon. 2021;7(9):e07994. doi: 10.1016/j.heliyon.2021.e07994.
Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res. 2002;19(6):875-80. doi: 10.1023/A:1016121319668.
Duong VA, Nguyen TT, Maeng HJ. Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method. Molecules. 2020;25(20):4781. doi: 10.3390/molecules25204781.
Yoon G, Park JW, Yoon IS. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery. J Pharm Investig. 2013;43(5):353-62. doi: 10.1007/s40005-013-0087-y.
Chauhan I, Yasir M, Verma M, Singh AP. Nanostructured lipid carriers: A groundbreaking approach for transdermal drug delivery. Adv Pharm Bull. 2020;10(2):150. doi: 10.34172/apb.2020.021.
Silva AC, Loureiro JA. A simple method for the preparation and characterization of nanostructured lipid carriers (NLC) formulations for cutaneous use. J Chem Educ. 2024;101(10):4333-8. doi: 10.1021/acs.jchemed.4c00503.
Dolatabadi S, Karimi M, Nasirizadeh S, Hatamipour M, Golmohammadzadeh S, Jaafari MR. Preparation, characterization and in vivo pharmacokinetic evaluation of curcuminoids-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs J Drug Deliv Sci Technol. 2021;62:102352. doi: 10.1016/j.jddst.2021.102352.
Ajiboye AL, Nandi U, Galli M, Trivedi V. Olanzapine loaded nanostructured lipid carriers via high shear homogenization and ultrasonication. Sci Pharm. 2021;89(2):25. doi: 10.3390/scipharm89020025.
Takemoto JK, Reynolds JK, Remsberg CM, Vega-Villa KR, Davies NM. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmac. 2008;47:703-20. doi: 10.2165/00003088-200847110-00002.
Chowdary KP, Reddy V. Formulation development studies on enhancement of solubility and dissolution rate of etoricoxib by cyclodextrin complexation. Asian J Chem. 2011;23(4):1445-48.
Brennan R, Wazaify M, Shawabkeh H, Boardley I, McVeigh J, Van Hout MC. A scoping review of non-medical and extra-medical use of non-steroidal anti-inflammatory drugs (NSAIDs). Drug Saf. 2021;44:917-28. doi: 10.1007/s40264-021-01085-9.
PubChem [Internet]. [Cited: 1-Aug-2024]. Available at: https://pubchem.ncbi.nlm.nih.gov/.
Basso J, Mendes M, Silva J, Sereno J, Cova T, Oliveira R, et al. Peptide-lipid nanoconstructs act site-specifically towards glioblastoma growth impairment. Eur J Pharm Biopharm 2020;155:177-89. doi: 10.1016/j.ejpb.2020.08.015.
Kirchrath JM, Schrr K. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract. Curr Med Chem. 2000;7(11):1121-9. doi: 10.2174/0929867003374219.
Lazzaroni M, Bianchi Porro G. Gastrointestinal side‐effects of traditional non‐steroidal anti‐inflammatory drugs and new formulations. Aliment Pharmacol Ther. 2004;20:48-58. doi: 10.1111/j.1365-2036.2004.02037.x.
Amedi D, Gazerani P. Deprescribing NSAIDs: The potential role of community pharmacists. Pharmacy. 2024;12(4):116. doi: 10.3390/pharmacy12040116.
Arfeen M, Srivastava A, Srivastava N, Khan RA, Al-mahmoud S, Mohammed HA. Design, classification, and adverse effects of NSAIDs: A review on recent advancements. Bioorg Med Chem. 2024;117899. doi: 10.1016/j.bmc.2024.117899.
Bawazeer S, El-Telbany DF, Al-Sawahli MM, Zayed G, Keed AA, Abdelaziz AE, Bawazeer. Effect of nanostructured lipid carriers on transdermal delivery of tenoxicam in irradiated rats. Drug Deliv. 2020;27(1):1218-30. doi: 10.1080/10717544.2020.1803448.
Lopes-de-Araújo J, Neves AR, Gouveia VM, Moura CC, Nunes C, Reis S. Oxaprozin-loaded lipid nanoparticles towards overcoming NSAIDs side-effects. Pharm Res. 2016;33:301-14. doi: 10.1007/s11095-015-1788-x.
Laine L. Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manag. 2003;25(2):32-40. doi: 10.1016/S0885-3924(02)00629-2.
Gönüllü Ü, Üner M, Yener G, Fatma Karaman EC, Aydoğmuş Z. Formulation and characterization of solid lipid nanoparticles, nanostructured lipid carriers and nanoemulsion of lornoxicam for transdermal delivery. Acta Pharm. 2015;65(1):1-3. doi: 10.1515/acph-2015-0009.
Sohail R, Mathew M, Patel KK, Reddy SA, Haider Z, Naria M, et al. Effects of non-steroidal anti-inflammatory drugs (NSAIDs) and gastroprotective NSAIDs on the gastrointestinal tract: a narrative review. Cureus. 2023;15(4): e37080. doi: 10.7759/cureus.37080.
Wirth T, Lafforgue P, Pham T. NSAID: Current limits to prescription. Joint Bone Spine. 2023; 91(4):105685. doi: 10.1016/j.jbspin.2023.105685.
Domper Arnal MJ, Hijos-Mallada G, Lanas A. Gastrointestinal and cardiovascular adverse events associated with NSAIDs. Expert Opin Drug Saf. 2022;21(3):373-84. doi: 10.1080/14740338.2021.1965988.
Anand A, Arya M, Singh G, Kaithwas G, A Saraf S. Design and development of resveratrol NLCs and their role in synaptic transmission of acetylcholine in C. elegans model. Curr Drug Ther. 2017;12(2):134-48. doi: 10.2174/1574885512666170529114325.
Anand A, Arya M, Kaithwas G, Singh G, Saraf SA. Sucrose stearate as a biosurfactant for development of rivastigmine containing nanostructured lipid carriers and assessment of its activity against dementia in C. elegans model. J Drug Deliv Sci Technol. 2019;49:219-26. doi: 10.1016/j.jddst.2018.11.021.
Fang CL, A Al-Suwayeh S, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol. 2013;7(1):41-55. doi: 10.2174/187221013804484827.
Kakadia PG, Conway BR. Lipid nanoparticles for dermal drug delivery. Curr Pharm Des. 2015;21(20):2823-9. doi: 10.2174/1381612821666150428143730.
Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv. 2006;13(3):175-87. doi: 10.1080/10717540500455975.
Jyothi VG, Ghouse SM, Khatri DK, Nanduri S, Singh SB, Madan J. Lipid nanoparticles in topical dermal drug delivery: Does chemistry of lipid persuade skin penetration? J Drug Deliv Sci Technol. 2022;69:103176. doi: 10.1016/j.jddst.2022.103176.
Puglia C, Bonina F. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin Drug Deliv. 2012;9(4):429-41. doi: 10.1517/17425247.2012.666967.
Kharwade RS, Mahajan NM. Formulation and evaluation of nanostructured lipid carriers based anti-inflammatory gel for topical drug delivery system. Asian J Pharm Clin Res. 2019;12:286-91. doi: 10.22159/ajpcr.2019.v12i4.32000.
Zahoor I, Sharma N, Behl T, Singh S. Diagnostic Analysis and graphical optimization of fenoprofen calcium-loaded nanostructured lipid carriers using design of experiments. Int J Pharm Qual Assur. 2022;13(3):240-6. doi: 10.25258/ijpqa.13.3.03.
Garg NK, Sharma G, Singh B, Nirbhavane P, Tyagi RK, Shukla R, et al. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder (s). Int J Pharm. 2017;517(1-2):413-31. doi: 10.1016/j.ijpharm.2016.12.010.
Sethuraman N, Shanmuganathan S, Sandhya K, Anbarasan B. Design, development and characterization of nano structured lipid carrier for topical delivery of aceclofenac. Indian J Pharm Educ Res. 2018;52(4):581-6. doi: 10.5530/ijper.52.4.67.
Phatak AA, Chaudhari PD. Development and evaluation of nanostructured lipid carrier (NLC) based topical delivery of an anti-inflammatory drug. J Pharm Res. 2013;7(8):677-85. doi: 10.1016/j.jopr.2013.08.020.
Han F, Yin R, Che X, Yuan J, Cui Y, Yin H, et al. Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: design, characterization and in vivo evaluation. Int J Pharm. 2012;439(1-2):349-57. doi: 10.1016/j.ijpharm.2012.08.040.
González-Mira E, Nikolić S, García ML, Egea MA, Souto EB, Calpena AC. Potential use of nanostructured lipid carriers for topical delivery of flurbiprofen. J Pharm Sci. 2011;100(1):242-51. doi: 10.1002/jps.22271.
Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm 2008;346(1-2):124-32. doi: 10.1016/j.ijpharm.2007.05.060.
Cirri M, Bragagni M, Mennini N, Mura P. Development of a new delivery system consisting in “drug–in cyclodextrin–in nanostructured lipid carriers” for ketoprofen topical delivery. Eur J Pharm Biopharm. 2012;80(1):46-53. doi: 10.1016/j.ejpb.2011.07.015.
Moghddam SM, Ahad A, Aqil M, Imam SS, Sultana Y. Optimization of nanostructured lipid carriers for topical delivery of nimesulide using Box–Behnken design approach. Artif Cells Nanomed Biotechnol. 2017;45(3):617-24. doi: 10.3109/21691401.2016.1167699.
Palei NN, Mohanta BC, Das MK, Sabapathi ML. Lornoxicam loaded nanostructured lipid carriers for topical delivery: Optimization, skin uptake and in vivo studies. J Drug Deliv Sci Technol. 2017;39:490-500. doi: 10.1016/j.jddst.2017.05.001.
Sütő B, Berkó S, Kozma G, Kukovecz Á, Budai-Szűcs M, Erős G, et al. Development of ibuprofen-loaded nanostructured lipid carrier-based gels: characterization and investigation of in-vitro and in vivo penetration through the skin. Int J Nanomedicine. 2016;1201-12. doi: 10.2147/IJN.S99198.
Czajkowska-Kośnik A, Szymańska E, Czarnomysy R, Jacyna J, Markuszewski M, Basa A, et al. Nanostructured lipid carriers engineered as topical delivery of etodolac: Optimization and cytotoxicity studies. Materials. 2021;14(3):596. doi: 10.3390/ma14030596.
Ricci M, Puglia C, Bonina F, Di Giovanni C, Giovagnoli S, Rossi C. Evaluation of indomethacin percutaneous absorption from nanostructured lipid carriers (NLC): in-vitro and in vivo studies. J Pharm Sci. 2005;94(5):1149-59. doi: 10.1002/jps.20335.
Khurana S, Bedi PM, Jain NK. Development of nanostructured lipid carriers for controlled delivery of mefenamic acid. Int J Biomed Nanosci Nanotechnol. 2012;2(3-4):232-50. doi: 10.1504/IJBNN.2012.051218.
Otarola JJ, Solis AK, Farias ME, Garrido M, Correa NM, Molina PG. Piroxicam-loaded nanostructured lipid carriers gel: Design and characterization by square wave voltammetry. Colloids Surf A: Physicochem Eng Asp. 2020;606:125396. doi: 10.1016/j.colsurfa.2020.125396.
Joshi M, Patravale V. Formulation and evaluation of nanostructured lipid carrier (NLC)–based gel of Valdecoxib. Drug Dev Ind Pharm. 2006;32(8):911-8. doi: 10.1080/03639040600814676.
Rincón M, Silva-Abreu M, Espinoza LC, Sosa L, Calpena AC, Rodríguez-Lagunas MJ, et al. Enhanced transdermal delivery of pranoprofen using a thermo-reversible hydrogel loaded with lipid nanocarriers for the treatment of local inflammation. Pharmaceuticals. 2021;15(1):22. doi: 10.3390/ph15010022.
Desai PR, Shah PP, Patlolla RR, Singh M. Dermal microdialysis technique to evaluate the trafficking of surface-modified lipid nanoparticles upon topical application. Pharm Res. 2012;29:2587-600. doi: 10.1007/s11095-012-0789-2.
Kumar L, Verma S, Singh M, Chalotra T, Utreja P. Advanced drug delivery systems for transdermal delivery of non-steroidal anti-inflammatory drugs: A review. Curr Drug Deliv. 2018;15(8):1087-99. doi: 10.2174/1567201815666180605114131.
Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev. 2004;56(5):675-711. doi: 10.1016/j.addr.2003.10.028.
Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov. 2004;3(2):115-24. doi: 10.1038/nrd1304.
Khurana S, Jain NK, Bedi PM. Development and characterization of a novel controlled release drug delivery system based on nanostructured lipid carriers gel for meloxicam. Life Sci. 2013;93(21):763-72. doi: 10.1016/j.lfs.2013.09.027.
Nguyen CN, Nguyen TT, Nguyen HT, Tran TH. Nanostructured lipid carriers to enhance transdermal delivery and efficacy of diclofenac. Drug Deliv Transl Res. 2017;7:664-73. doi: 10.1007/s13346-017-0415-2.
Kawadkar J, Pathak A, Kishore R, Chauhan MK. Formulation, characterization and in-vitro–in vivo evaluation of flurbiprofen-loaded nanostructured lipid carriers for transdermal delivery. Drug Dev Ind Pharm. 2013;39(4):569-78. doi: 10.3109/03639045.2012.686509.
Gao S, Tian B, Han J, Zhang J, Shi Y, Lv Q, Li K. Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema. Int J Nanomedicine. 2019:6135-50. doi: 10.2147/IJN.S205295.
Rincón M, Calpena AC, Fabrega MJ, Garduño-Ramírez ML, Espina M, Rodríguez-Lagunas MJ, et al. Development of pranoprofen loaded nanostructured lipid carriers to improve its release and therapeutic efficacy in skin inflammatory disorders. Nanomaterials. 2018;8(12):1022. doi: 10.3390/nano8121022.
Garg NK, Tandel N, Bhadada SK, Tyagi RK. Nanostructured lipid carrier–mediated transdermal delivery of aceclofenac hydrogel present an effective therapeutic approach for inflammatory diseases. Front Pharmacol. 2021;12:713616. doi: 10.3389/fphar.2021.713616.
Radwan R, El-Badry M, Fetih G, Allam A, Elsabahy M. Development and characterization of nanostructured lipid carriers for transdermal delivery of meloxicam. Bull Pharm Sci. 2019;42(1):51-62. doi: 10.21608/bfsa.2019.62265.
Bhaskar K, Anbu J, Ravichandiran V, Venkateswarlu V, Rao YM. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in-vitro, ex-vivo and in vivo studies. Lipids Health Dis. 2009;8:1-5. doi: 10.1186/1476-511X-8-6.
Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res. 2010;29(6):596-609. doi: 10.1016/j.preteyeres.2010.08.002.
Omerović N, Vranić E. Application of nanoparticles in ocular drug delivery systems. Health Technol. 2020;10(1):61-78. doi: 10.1007/s12553-019-00381-w.
Puglia C, Offerta A, Carbone C, Bonina F, Pignatello R, Puglisi G. Lipid nanocarriers (LNC) and their applications in ocular drug delivery. Curr Med Chem. 2015;22(13):1589-602. doi: 10.2174/0929867322666150209152259.
Araújo J, Gonzalez E, Egea MA, Garcia ML, Souto EB. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomed: Nanotechnol Biol Med. 2009;5(4):394-401. doi: 10.1016/j.nano.2009.02.003.
Souto EB, Doktorovova S, Gonzalez-Mira E, Egea MA, Garcia ML. Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs. Curr Eye Res. 2010;35(7):537-52. doi: 10.3109/02713681003760168.
Gonzalez-Mira E, Egea MA, Souto EB, Calpena AC, García ML. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology. 2010;22(4):045101. doi: 10.1088/0957-4484/22/4/045101.
Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf B Biointerfaces. 2010;81(2):412-21. doi: 10.1016/j.colsurfb.2010.07.029.
Li X, Nie SF, Kong J, Li N, Ju CY. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm. 2008;363(1-2):177-82. doi: 10.1016/j.ijpharm.2008.07.017.
Almeida H, Lobão P, Frigerio C, Fonseca J, Silva R, Palmeira-de-Oliveira A, et al. New thermoresponsive eyedrop formulation containing ibuprofen loaded-nanostructured lipid carriers (NLC): development, characterization and biocompatibility studies. Curr Drug Deliv. 2016;13(6):953-70. doi: 10.2174/1567201813666151111143434.
Almeida H, Lobão P, Frigerio C, Fonseca J, Silva R, Quaresma P, Lobo JM, Amaral MH. Development of mucoadhesive and thermosensitive eyedrops to improve the ophthalmic bioavailability of ibuprofen. J Drug Deliv Sci Technol. 2016;35:69-80. doi: 10.1016/j.jddst.2016.04.010.
Yu S, Tan G, Liu D, Yang X, Pan W. Nanostructured lipid carrier (NLC)-based novel hydrogels as potential carriers for nepafenac applied after cataract surgery for the treatment of inflammation: design, characterization and in-vitro cellular inhibition and uptake studies. RSC Adv. 2017;7(27):16668-77. doi: 10.1039/C7RA00552K.
Almeida H, Lobão P, Frigerio C, Fonseca J, Silva R, Sousa Lobo JM, Amaral MH. Preparation, characterization and biocompatibility studies of thermoresponsive eyedrops based on the combination of nanostructured lipid carriers (NLC) and the polymer Pluronic F-127 for controlled delivery of ibuprofen. Pharm Dev Technol. 2017;22(3):336-49. doi: 10.3109/10837450.2015.1125922.
Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm. 2011;403(1-2):185-91. doi: 10.1016/j.ijpharm.2010.10.013.
Gamboa JM, Leong KW. In-vitro and in vivo models for the study of oral delivery of nanoparticles. Adv Drug Deliv Rev. 2013;65(6):800-10. doi: 10.1016/j.addr.2013.01.003.
Vinarov Z, Abdallah M, Agundez JA, Allegaert K, Basit AW, Braeckmans M, et al. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. Eur J Pharm Sci. 2021;162:105812. doi: 10.1016/j.ejps.2021.105812.
Tan SL, Billa N. Improved bioavailability of poorly soluble drugs through gastrointestinal muco-adhesion of lipid nanoparticles. Pharmaceutics. 2021;13(11):1817. doi: 10.3390/pharmaceutics13111817.
Kawish SM, Ahmed S, Gull A, Aslam M, Pandit J, Aqil M, Sultana Y. Development of nabumetone loaded lipid nano-scaffold for the effective oral delivery; optimization, characterization, drug release and pharmacodynamic study. J Mol Liq. 2017;231:514-22. doi: 10.1016/j.molliq.2017.01.107.
Tyagi P, Subramony JA. Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small. J Control Release. 2018;272:159-68. doi: 10.1016/j.jconrel.2018.01.009.
Gulati N, Gupta H. Parenteral drug delivery: a review. Recent Pat Drug Deliv Formul. 2011;5(2):133-45. doi: 10.2174/187221111795471391.
Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target. 2012;20(10):813-30. doi: 10.3109/1061186X.2012.716845.
Guilherme VA, Ribeiro LN, Alcântara AC, Castro SR, Rodrigues da Silva GH, da Silva CG, et al. Improved efficacy of naproxen-loaded NLC for temporomandibular joint administration. Sci Rep. 2019;9(1):11160. doi: 10.1038/s41598-019-47486-w.
Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages. Res Pharm Sci. 2018;13(4):288-303. doi: 10.4103/1735-5362.235156.
Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PN, Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release 2010;144(2):233-41. doi: 10.1016/j.jconrel.2010.02.006.
Gilhotra RM, Ikram M, Srivastava S, Gilhotra N. A clinical perspective on mucoadhesive buccal drug delivery systems. J Biomed Res. 2014;28(2):81. doi: 10.7555/JBR.27.20120136.
Macedo AS, Castro PM, Roque L, Thomé NG, Reis CP, Pintado ME, et al. Novel and revisited approaches in nanoparticle systems for buccal drug delivery. J Control Release. 2020;320:125-141. doi: 10.1016/j.jconrel.2020.01.006.
Kianfar F, Chowdhry BZ, Antonijevic MD, Boateng JS. Novel films for drug delivery via the buccal mucosa using model soluble and insoluble drugs. Drug Dev Ind Pharm 2012;38(10):1207-1220. doi: 10.3109/03639045.2011.644294
Sankar V, Hearnden V, Hull K, Juras DV, Greenberg MS, Kerr AR, et al. Local drug delivery for oral mucosal diseases: challenges and opportunities. Oral Dis. 2011;17:73-84. doi: 10.1111/j.1601-0825.2011.01793.x.
Şenel S, Hıncal AA. Drug permeation enhancement via buccal route: possibilities and limitations. J Control Release. 2001;72(1-3):133-44. doi: 10.1016/S0168-3659(01)00269-3.
Jacob S, Nair AB, Boddu SH, Gorain B, Sreeharsha N, Shah J. An updated overview of the emerging role of patch and film-based buccal delivery systems. Pharmaceutics. 2021;13(8):1206. doi: 10.3390/pharmaceutics13081206.
Marques AC, Rocha AI, Leal P, Estanqueiro M, Lobo JM. Development and characterization of mucoadhesive buccal gels containing lipid nanoparticles of ibuprofen. Int J Pharm. 2017;533(2):455-62. doi: 10.1016/j.ijpharm.2017.04.025.
Hv RR, Bhattacharyya S. In-vitro evaluation of mucoadhesive in situ nanogel of celecoxib for buccal delivery. Ann Pharm Fr. 2021;79:418-30. doi: 10.1016/j.pharma.2021.01.006.
Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131-S155. doi: 10.1016/S0169-409X(02)00118-7.
Varshosaz J, Eskandari S, Tabbakhian M. Freeze-drying of nanostructure lipid carriers by different carbohydrate polymers used as cryoprotectants. Carbohydr Polym. 2012;88(4):1157-63. doi: 10.1016/j.carbpol.2012.01.051.
Rouco H, Diaz-Rodriguez P, Guillin A, Remuñán-López C, Landin M. A traffic light system to maximize carbohydrate cryoprotectants’ effectivity in nanostructured lipid carriers’ lyophilization. Pharmaceutics. 2021;13(9):1330. doi: 10.3390/pharmaceutics13091330.
Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006;58(15):1688-713. doi: 10.1016/j.addr.2006.09.017.
Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomed: Nanotechnol Biol Med. 2016;12(1):143-61. doi: 10.1016/j.nano.2015.09.004.
Obeidat WM, Schwabe K, Müller RH, Keck CM. Preservation of nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2010;76(1):56-67. doi: 10.1016/j.ejpb.2010.05.001.
Hommoss A. Preservative system development for argan oil-loaded nanostructured lipid carriers. Pharmazie. 2011;66(3):187-91. doi: 10.1691/ph.2011.0272.
Dhiman N, Awasthi R, Sharma B, Kharkwal H, Kulkarni GT. Lipid nanoparticles as carriers for bioactive delivery. Front Chem. 2021;9:580118. doi: 10.3389/fchem.2021.580118.
Doktorovova S, Kovačević AB, Garcia ML, Souto EB. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in-vitro and in vivo evaluation. Eur J Pharm Biopharm. 2016;108:235-52. doi: 10.1016/j.ejpb.2016.08.001.
Doktorovova S, Souto EB, Silva AM. Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers–a systematic review of in-vitro data. Eur J Pharm Biopharm. 2014;87(1):1-8. doi: 10.1016/j.ejpb.2014.02.005.
Brugè F, Damiani E, Puglia C, Offerta A, Armeni T, Littarru GP, et al. Nanostructured lipid carriers loaded with CoQ10: Effect on human dermal fibroblasts under normal and UVA-mediated oxidative conditions. Int J Pharm. 2013;455(1-2):348-56. doi: 10.1016/j.ijpharm.2013.06.075.
Brugè F, Damiani E, Marcheggiani F, Offerta A, Puglia C, Tiano L. A comparative study on the possible cytotoxic effects of different nanostructured lipid carrier (NLC) compositions in human dermal fibroblasts. Int J Pharm. 2015;495(2):879-85. doi: 10.1016/j.ijpharm.2015.09.033.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).